1. Jiang, Wenyan, Wei, Qiong, Xie, Haiqin, He, Haiyan, Lv, Xuedong. 2023. Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma. In Analytical cellular pathology (Amsterdam), 2023, 4522045. doi:10.1155/2023/4522045. https://pubmed.ncbi.nlm.nih.gov/37416927/
2. Chen, Shengmiao, Wu, Yiran, Gao, Yang, Zhao, Suwen, Fan, Gaofeng. 2023. Allosterically inhibited PFKL via prostaglandin E2 withholds glucose metabolism and ovarian cancer invasiveness. In Cell reports, 42, 113246. doi:10.1016/j.celrep.2023.113246. https://pubmed.ncbi.nlm.nih.gov/37831605/
3. Adekeye, Adeseye, Agarwal, Divyansh, Nayak, Anupma, Tchou, Julia. 2021. PTGES3 is a Putative Prognostic Marker in Breast Cancer. In The Journal of surgical research, 271, 154-162. doi:10.1016/j.jss.2021.08.033. https://pubmed.ncbi.nlm.nih.gov/34920330/
4. Wang, Han, Sun, Peng, Yao, Ruoyu, Yao, Jia, He, Kun. 2023. Comprehensive pan-cancer analysis of PTGES3 and its prognostic role in hepatocellular carcinoma. In Frontiers in oncology, 13, 1158490. doi:10.3389/fonc.2023.1158490. https://pubmed.ncbi.nlm.nih.gov/37274225/
5. Gao, Pengxiang, Zou, Kang, Xiao, Li, Zeng, Zhenguo, Zhang, Wei. 2022. High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. In International immunopharmacology, 110, 108954. doi:10.1016/j.intimp.2022.108954. https://pubmed.ncbi.nlm.nih.gov/35820363/
智鼠故事 
